ETFMG Treatments, Testing and Advancements ETF
           
Schedule of Investments
           
June 30, 2023 (Unaudited)
           
   
Shares
   
Value
 
COMMON STOCKS - 99.5%
           
Canada - 4.4%
           
Biotechnology - 1.0% (d)
           
Arbutus Biopharma Corp. (a)
   
53,155
   
$
122,257
 
VBI Vaccines, Inc. (a)
   
10
     
33
 
XBiotech, Inc. (a)
   
9,739
     
57,850
 
Total Biotechnology
           
180,140
 
Life Sciences Tools & Services - 3.4%
               
AbCellera Biologics, Inc. (a)(b)
   
92,379
     
596,768
 
Total Canada
           
776,908
 
                 
Cayman Islands - 3.3%
               
Biotechnology - 3.3% (d)
               
Zai Lab, Ltd. - ADR (a)(b)
   
20,923
     
580,195
 
                 
France - 0.8%
               
Pharmaceuticals - 0.8%
               
Sanofi - ADR
   
2,631
     
141,811
 
                 
Germany - 6.1%
               
Biotechnology - 6.1% (d)
               
BioNTech SE - ADR (a)
   
9,947
     
1,073,580
 
                 
Japan - 0.7%
               
Pharmaceuticals - 0.7%
               
Takeda Pharmaceutical Co., Ltd. - ADR (b)
   
8,356
     
131,273
 
                 
Netherlands - 4.7%
               
Biotechnology - 4.7% (d)
               
CureVac NV (a)(b)
   
71,619
     
746,270
 
InflaRx NV (a)
   
17,314
     
77,220
 
Total Biotechnology
           
823,490
 
                 
United Kingdom - 5.8%
               
Biotechnology - 4.3% (d)
               
Immunocore Holdings PLC - ADR (a)(b)
   
12,542
     
752,018
 
Pharmaceuticals - 1.5%
               
AstraZeneca PLC - ADR
   
1,823
     
130,472
 
GSK PLC - ADR
   
3,928
     
139,994
 
Total Pharmaceuticals
           
270,466
 
Total United Kingdom
           
1,022,484
 
                 
United States - 73.7%
               
Biotechnology - 37.8% (d)
               
AbbVie, Inc.
   
995
     
134,056
 
Alnylam Pharmaceuticals, Inc. (a)
   
5,489
     
1,042,581
 
Altimmune, Inc. (a)
   
15,771
     
55,672
 
Arcturus Therapeutics Holdings, Inc. (a)(b)
   
8,499
     
243,751
 
BioCryst Pharmaceuticals, Inc. (a)(b)
   
60,450
     
425,568
 
CEL-SCI Corp. (a)(b)
   
14,307
     
34,480
 
Chimerix, Inc. (a)
   
28,343
     
34,295
 
Cue Biopharma, Inc. (a)
   
13,815
     
50,425
 
Dynavax Technologies Corp. (a)(b)
   
41,110
     
531,141
 
Emergent BioSolutions, Inc. (a)
   
16,141
     
118,636
 
Enanta Pharmaceuticals, Inc. (a)
   
6,737
     
144,172
 
Gilead Sciences, Inc.
   
1,742
     
134,256
 
Gritstone bio, Inc. (a)
   
28,448
     
55,474
 
HilleVax, Inc. (a)
   
12,542
     
215,597
 
Icosavax, Inc. (a)
   
15,907
     
157,957
 
ImmunityBio, Inc. (a)(b)
   
139,494
     
387,793
 
Inovio Pharmaceuticals, Inc. (a)(b)
   
84,065
     
37,535
 
Invivyd, Inc. (a)
   
35,029
     
36,780
 
Moderna, Inc. (a)
   
8,059
     
979,169
 
Novavax, Inc. (a)(b)
   
27,613
     
205,165
 
Ocugen, Inc. (a)(b)
   
83,484
     
45,340
 
Regeneron Pharmaceuticals, Inc. (a)
   
182
     
130,774
 
Vaxart, Inc. (a)(b)
   
43,385
     
31,671
 
Vaxcyte, Inc. (a)
   
13,727
     
685,526
 
Vaxxinity, Inc. - Class A (a)(b)
   
40,487
     
102,027
 
Vir Biotechnology, Inc. (a)(b)
   
25,677
     
629,857
 
Total Biotechnology
           
6,649,698
 
Health Care Equipment & Supplies - 6.1%
               
Abbott Laboratories
   
1,291
     
140,745
 
Cue Health, Inc. (a)
   
48,511
     
17,901
 
Hologic, Inc. (a)
   
1,678
     
135,868
 
OraSure Technologies, Inc. (a)(b)
   
23,441
     
117,439
 
QuidelOrtho Corp. (a)(b)
   
8,061
     
667,934
 
Total Health Care Equipment & Supplies
           
1,079,887
 
Health Care Providers & Services - 18.1%
               
Enzo Biochem, Inc. (a)
   
15,890
     
29,238
 
Fulgent Genetics, Inc. (a)
   
9,503
     
351,896
 
Laboratory Corp. of America Holdings
   
4,875
     
1,176,483
 
OPKO Health, Inc. (a)(b)
   
247,278
     
536,593
 
Quest Diagnostics, Inc.
   
7,726
     
1,085,967
 
Total Health Care Providers & Services
           
3,180,177
 
Life Sciences Tools & Services - 5.8%
               
Adaptive Biotechnologies Corp. (a)
   
46,173
     
309,821
 
Bio-Rad Laboratories, Inc. - Class A (a)
   
1,859
     
704,784
 
Total Life Sciences Tools & Services
           
1,014,605
 
Pharmaceuticals - 6.0%
               
AN2 Therapeutics, Inc. (a)(b)
   
6,215
     
52,828
 
Atea Pharmaceuticals, Inc. (a)
   
26,684
     
99,798
 
CorMedix, Inc. (a)
   
14,519
     
57,568
 
Eli Lilly and Co.
   
304
     
142,569
 
Johnson & Johnson
   
859
     
142,181
 
Merck & Co, Inc.
   
1,197
     
138,122
 
Paratek Pharmaceuticals, Inc. (a)
   
18,328
     
40,505
 
Pfizer, Inc.
   
3,492
     
128,087
 
Scilex Holding Co. (a)
   
23,669
     
131,834
 
SIGA Technologies, Inc.
   
22,802
     
115,150
 
Total Pharmaceuticals
           
1,048,642
 
Total United States
           
12,973,009
 
TOTAL COMMON STOCKS (Cost $29,882,764)
           
17,522,750
 
                 
INVESTMENTS PURCHASED WITH PROCEEDS FROM SECURITIES LENDING COLLATERAL - 32.8%
               
ETFMG Sit Ultra Short ETF (e)
   
25,000
     
1,212,250
 
Mount Vernon Liquid Assets Portfolio, LLC, 5.22% (c)
   
4,561,148
     
4,561,148
 
TOTAL INVESTMENTS PURCHASED WITH PROCEEDS FROM SECURITIES LENDING COLLATERAL (Cost $5,805,123)
           
5,773,398
 
                 
SHORT-TERM INVESTMENTS - 0.6%
               
Money Market Funds - 0.6%
               
First American Government Obligations Fund - Class X, 5.01% (c)
   
96,824
     
96,824
 
TOTAL SHORT-TERM INVESTMENTS (Cost $96,824)
           
96,824
 
                 
Total Investments (Cost $35,784,711) - 132.9%
           
23,392,972
 
Liabilities in Excess of Other Assets - (32.9)%
           
(5,785,253
)
TOTAL NET ASSETS - 100.0%
         
$
17,607,719
 

Percentages are stated as a percent of net assets.
 
 
ADR
American Depositary Receipt
     
PLC
Public Limited Company
     
(a)
Non-income producing security.
     
(b)
All or a portion of this security was out on loan at June 30, 2023.
     
(c)
The rate shown is the annualized seven-day yield at period end.
     
(d)
As of June 30, 2023 the Fund had a significant portion of its assets in the Biotechnology Industry.
     
(e)
Affiliated security. A schedule of the Fund’s investments in securities of affiliated issuers held during the period ended June 30, 2023 is set forth below.
         
The Global Industry Classification Standard (GICS®) was developed by and/or is the exclusive property of MSCI, Inc. and Standard & Poor’s Financial Services LLC (“S&P”). GICS is a service mark of MSCI and S&P and has been licensed for use by U.S. Bancorp Fund Services, LLC, doing business as U.S. Bank Global Fund Services (“Fund Services”).
         
The accompanying notes are an integral part of these financial statements.



Security Name
Value at
September 30,
2022
Purchases
Sales
Net Realized Gain
(Losses)
Net Change in
Unrealized
Appreciation
(Depreciation)
Dividend
Income
Value at
June 30,
2023
Ending Shares
ETFMG Sit Ultra Short ETF
 $            1,201,875
 $                       -
 $                      -
 $                     -
 $                10,375
 $             -
 $            1,212,250
                  25,000


 
ETF Managers Trust

The following is a summary of significant accounting policies consistently followed by ETFMG Prime Junior Silver Miners ETF (“SILJ”), ETFMG Prime 2x Daily Junior Silver Miners ETF (“SILX), ETFMG Prime Cyber Security ETF (“HACK”), ETFMG Prime Mobile Payments ETF (“IPAY”), ETFMG Sit Ultra Short ETF (“VALT”), ETFMG Travel Tech ETF (“AWAY”), ETFMG Treatments, Testing and Advancements ETF (“GERM”), ETFMG Alternative Harvest U.S. ETF (“MJUS”), ETFMG Alternative Harvest ETF (“MJ”), ETFMG 2x Daily Alternative Harvest ETF (“MJXL”), Wedbush ETFMG Video Game Tech ETF (“GAMR”), Wedbush ETFMG Global Cloud Technology ETF (“IVES”), BlueStar Israel Technology ETF (“ITEQ”), Etho Climate Leadership U.S. ETF (“ETHO”) and AI Powered Equity ETF (“AIEQ”)(each a “Fund,” or collectively the “Funds”).
 
 
 
Security Valuation. Securities listed on a securities exchange, market or automated quotation system for which quotations are readily available (except for securities traded on NASDAQ), including securities traded over the counter, are valued at the last quoted sale price on the primary exchange or market (foreign or domestic) on which they are traded on the valuation date (or at approximately 4:00 pm Eastern Time if a security’s primary exchange is normally open at that time), or, if there is no such reported sale on the valuation date, at the most recent quoted bid price. For securities traded on NASDAQ, the NASDAQ Official Closing Price will be used.
 
Securities for which quotations are not readily available are valued at their respective fair values as determined in good faith by the Board of Trustees (the “Board”). When a security is “fair valued,” consideration is given to the facts and circumstances relevant to the particular situation, including a review of various factors set forth in the pricing procedures adopted by the Funds’ Board. The use of fair value pricing by a Fund may cause the net asset value of its shares to differ significantly from the net asset value that would be calculated without regard to such considerations. As of June 30, 2023, AIEQ, HACK, IPAY, GAMR, VALT, AWAY, GERM, MJUS, MJXL, SILX, IVES, ITEQ and ETHO did not hold any fair valued securities. As of June 30, 2023, SILJ held three fair valued securities and MJ held one fair valued security.
 
As described above, the Funds utilize various methods to measure the fair value of their investments on a recurring basis. U.S. GAAP establishes a hierarchy that prioritizes inputs to valuation methods. The three levels of inputs are:
 
 
 
 
Level 1
Unadjusted quoted prices in active markets for identical assets or liabilities that the Funds have the ability to access.
 
 
Level 2
Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.
 
Level 3
Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available; representing the Funds’ own assumptions about the assumptions a market participant would use in valuing the asset or liability and would be based on the best information available.
 
 
 
 
The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.
 
The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level input that is significant to the fair value measurement in its entirety.
 
The following is a summary of the inputs used to value the Funds’ investments as of June 30, 2023:
 
GERM
                       
Assets^
 
Level 1
   
Level 2
   
Level 3
   
Total
 
Common Stocks
 
$
17,522,750
   
$
-
   
$
-
   
$
17,522,750
 
Short-Term Investments
   
96,824
     
-
     
-
     
96,824
 
ETFMG Sit Ultra Short ETF**
   
1,212,250
     
-
     
-
     
1,212,250
 
Investments Purchased with Securities Lending Collateral*
   
-
     
-
     
-
     
4,561,148
 
Total Investments in Securities
 
$
18,831,824
   
$
-
   
$
-
   
$
23,392,972
 
 
(1)   Includes a security valued at $0.
               
^    See Schedule of Investments for classifications by country and industry
             
*    Certain investments that are measured at fair value used the net asset value per share (or its equivalent) practical expedient have not been
   
      categorized in the fair value hierarchy.  The fair value amounts presented in the table are intended to permit reconciliation of the fair value
   
      hierarchy to the amounts presented in the Schedules of Investments.
               
** Investment was purchased with collateral.
               
*** Swap contracts are derivative instruments, which are presented at the unrealized appreciation/depreciation on the instrument

Amplify Junior Silver Mi... (AMEX:SILJ)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Amplify Junior Silver Mi....
Amplify Junior Silver Mi... (AMEX:SILJ)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Amplify Junior Silver Mi....